A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Prior treatment

• B cell-targeted therapy agents administered within 6 months before GNC-038 treatment;
• Received CAR-T therapy within 6 months before GNC-038 treatment;
• Use of anti-TNF drugs within 8 weeks before administration;
• Use of any JAK inhibitor within 2 weeks before dosing;
• Antimalarial drugs, sulfasalazine, penicillamine, etc. were used within 4 weeks before the drug administration;
• Use of phytochemicals within 4 weeks before administration;
• The use of other biological agents or other non-B cell depleting clinical investigational drugs before drug administration did not exceed 5 half-lives;
• Received an intra-articular injection within 4 weeks before study entry;
• Receipt of any investigational drug within 28 days before dose or within 5 half-lives of the investigational drug;
• A history of any cardiovascular disease described in the protocol within 6 months before screening;
• A history of ≥ grade 2 bleeding within 30 days before screening or the need for long-term continuous anticoagulant therapy;
• Having a history or evidence of suicidal thoughts within 6 months before signing ICF, which is considered by the researcher to be a significant risk of suicide;
• Investigators considered a history of alcohol or drug abuse in the 12 months before screening;
• Any active infection requiring systemic antibiotic treatment within 2 weeks before or during screening;

Other illness

• Confirmed diagnosis of another autoimmune rheumatic disease;
• History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation;
• Presence of: 1) active hepatitis B at screening; 2) hepatitis C or HIV infection; 3) syphilis infection;
• Poorly controlled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg);
• Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of GNC-038;
• Diagnosed with malignant tumor within 5 years before signing ICF;
• History of splenectomy;
• A history of severe and/or disseminated viral infection;
• Active M. tuberculosis infection may be present.

Lab values

• Prolonged QT interval at rest (QTcf \> 450 msec in men or \> 470 msec in women);

Other

• ACR functional class IV or bedridden/wheelchair-bound;
• Women who are pregnant or breastfeeding;
• Other situations of poor compliance, unwillingness or inability to comply with the study protocol as judged by the investigator;

• Subjects can understand the informed consent form, voluntarily participate in and sign the informed consent form;
• No gender limit;
• Age: ≥18 years old and ≤75 years old;
• Life expectancy greater than 6 months;
• Patients diagnosed with rheumatoid arthritis according to 1987 or 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria;
• Patients were moderately to severely active RA at the time of screening;
• A stable standard-of-care regimen was maintained for at least 30 days before the first dose;
• Previous treatment with antirheumatic drugs other than MTX: Leflunomide should be discontinued at least 8 weeks before the start of study treatment or cholestyramine should be used for 14 days;
• Erythrocyte sedimentation rate (ESR) \> 28mm/hr or C-reactive protein (CRP) \> 10mg/L;
• Positive rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies;
• There were CD19+ B cells in the peripheral blood of the patient;
• Diagnosis of rheumatoid arthritis (RA) more than 6 months;
• The organ function level before the first administration met the requirements;
• Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 24 weeks after the termination of treatment and should commit not to donate eggs (eggs, oocytes)/sperm for assisted reproduction for 1 year after the last study treatment. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
• Participants were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.